Treatment Choices for Recurrent dMMR Endometrial Cancer
Exploring treatment options for patients with recurrent mismatch repair deficient endometrial cancer, including the choice between single-agent checkpoint inhibitors and chemo-immunotherapy combinations, with insights from GARNET and KEYNOTE-158 studies.
EP: 1.Changing Landscape of Endometrial Cancer: Incidence and Classification
EP: 2.Optimal Workup Strategies in Advanced Endometrial Cancer
EP: 3.Factors in Frontline Treatment Decision Making for Endometrial Cancer
EP: 4.Assessing Response to First-Line Therapy in Advanced Endometrial Cancer: Clinical Factors
EP: 5.Chronic Challenges in Endometrial Cancer: Recurrence and Second-Line Therapy
Now Viewing
EP: 6.Treatment Choices for Recurrent dMMR Endometrial Cancer
EP: 7.HER2-Positive Endometrial Cancer: A Targeted Approach to Treatment
EP: 8.Treatment for Recurrent Endometrial Cancer: Chemotherapy or Lenvatinib + Pembrolizumab
EP: 9.Endometrial Cancer: Managing Toxicities in Lenvatinib and Pembrolizumab
EP: 10.Revolutionizing Frontline Therapy for Endometrial Cancer: Checkpoint Inhibitors and MMR Status
EP: 11.Expanding Horizons in Endometrial Cancer Treatment: Beyond Chemotherapy
EP: 12.Diversity and Access to Clinical Trials in Endometrial Cancer
Related Videos
Related Content
